UniProtKB/Swiss-Prot P08253: Variant p.Val621Leu

72 kDa type IV collagenase
Gene: MMP2
Feedback?

Variant information Variant position:

621 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Valine (V) to Leucine (L) at position 621 (V621L, p.Val621Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs16955280 [ dbSNP | Ensembl ]

Sequence information Variant position:

621 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

660 The length of the canonical sequence.
Location on the sequence:

GFPKLIADAWNAIPDNLDAV V DLQGGGHSYFFKGAYYLKLE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         GFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLE

Mouse                         GFPKLIADSWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLE

Rat                           GFPKLIADSWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLE

Bovine                        GFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLE

Rabbit                        GFPRLIADAWNAIPDHLDAVVDLQGSGHSYFFKGTYYLKLE

Chicken                       ATPKFIADSWNGVPDNLDAVLGLTDSGYTYFFKDQYYLQME

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	110 – 660	72 kDa type IV collagenase
Chain	445 – 660	PEX
Repeat	614 – 660	Hemopexin 4
Region	414 – 660	Required for inhibitor TIMP2 binding
Binding site	618 – 618
Disulfide bond	469 – 660
Beta strand	618 – 622

Literature citations
Submission
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS VAL-447 AND LEU-621;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.